🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsClinical Trials & ResearchCagriSema (amylin + semaglutide) — my results so far Page 6

CagriSema (amylin + semaglutide) — my results so far

Dr.NutriCornell Wed, Apr 1, 2026 at 9:59 AM 31 replies 1,170 viewsPage 6 of 7
greg_boulder
Member
345
1,567
Jul 2024
Boulder, CO
Apr 5, 2026 at 3:14 AM#26
Dr.SleepRoch said:
The distinction that resolves most of these threads is between what is true on average and what is true for one person.

There is a second half to this that has not been said yet. It is worth asking what the claim would look like if it were false. If nothing would look different, it is not a claim about the world and no amount of discussion will settle it.

8 8denise_HTX, raj_cambridge, ingrid_STO and 5 others
Reply Quote Save Share Report
dan_philly
Member
456
2,123
Jul 2024
Philadelphia, PA
Apr 5, 2026 at 12:59 PM#27

One concrete data point for the thread. Practical: whatever you change, write down the date and the reason. In three months the reason is what you will have forgotten, and the reason is what makes the record worth having.

That is the short version; the long version is somebody else's post.

7 7AmyNC_wife, SkepticalSean, Dr.CardioMD and 4 others
Reply Quote Save Share Report
wanda_boise
Member
412
1,890
Aug 2024
Boise, ID
Apr 5, 2026 at 10:44 PM#28

A narrower follow-up, since the general answer is now clear:

How much of the between-person variation is pharmacokinetic and how much is just adherence measured badly?

Last edited: Apr 6, 2026 at 3:44 AM
6 6pam_columbus, nick_SD_fit, ben_calgary and 3 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
pete_RVA
Member
178
890
Dec 2024
Richmond, VA
Apr 6, 2026 at 8:28 AM#29
dan_philly said:
Practical: whatever you change, write down the date and the reason.

Filing a mild objection. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit. Filing an objection on the n=1 problem. Personal experience is genuine evidence about one person and very weak evidence about anybody else, and this thread keeps promoting the first into the second.

5 5MikeNYC_runner and 2 others
Reply Quote Save Share Report
Dr.NutriCornell
Senior Member
1,345
6,234
Mar 2024
Ithaca, NY
Apr 6, 2026 at 6:12 PM#30

Closing the loop on my own question.

Following this thread I went back and re-read the extension data properly. The point about trough rather than peak explains the pattern I was seeing on day six, which I had been blaming on the vial.

33 8pat_auckland, Dr.GastroMayo, JakeBK_lifts and 30 others
Reply Quote Save Share Report

Similar Threads

FLOW trial: semaglutide renal outcomes — NEJM publication review14 replies
SELECT trial: semaglutide 2.4mg cardiovascular outcomes — 4yr data9 replies
TRIUMPH program (retatrutide) — Phase 3 trial design and endpoints13 replies
Orforglipron ATTAIN trials — oral non-peptide GLP-1 agonist8 replies
CagriSema (amylin + semaglutide) — REDEFINE Phase 3 results20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register